Certain psychedelic drugs have shown promise in treating mental illnesses, but the potential increase in at-home drug use raises concerns. A recent study suggests that MDMA, also known as Ecstasy or Molly, can alleviate symptoms of post-traumatic stress disorder (PTSD), and it may receive FDA approval by 2024. The study was sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), an organization that focuses on the medical, legal, and cultural aspects of psychedelic and marijuana use. MAPS founder Rick Doblin expressed optimism about the potential approval of MDMA-assisted therapy for PTSD. However, it is worth noting that Australia has become the first country to permit certain patients with depression and PTSD to use psychedelics under the guidance of psychiatrists. The study found that 86% of the participants in the MDMA group experienced improvement, compared to 69% in the placebo group. Additionally, 72% of those in the MDMA group no longer met the criteria for a PTSD diagnosis, compared to 48% in the placebo group. The FDA has designated psilocybin, the psychoactive compound in psychedelic mushrooms, as a “breakthrough therapy,” expediting its development and review. While researchers have received federal grants and the FDA has released draft guidance for clinical trials, the American Psychiatric Association has not endorsed the use of psychedelics in treatment. It is important to note that further research is needed to fully understand the efficacy and risks associated with psychedelics.
